课题基金 / 基金详情

项目摘要

项目成果

Jonathan D. Licht的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):多发性骨髓瘤(MM)代表浆细胞的恶性转化,分化,生发后中心b细胞适应于产生大量抗体。多发性骨髓瘤是最常见的血液系统恶性肿瘤之一,尽管出现了几种新的治疗方法,如蛋白体抑制剂和沙利度胺以及干细胞移植巩固的使用,但这种疾病是无法治愈的,中位生存期约为3年。这种疾病的发病机制多年来一直很不清楚,但在过去十年中,基于涉及免疫球蛋白重链(IgH)的一致性染色体易位的特征,已经取得了进展。这些易位暗示了骨髓瘤发病机制中的特定基因。MMSET (MULTIPLE MYELOMA SET DOMAIN)基因在t(4;14)易位的断点处被鉴定,存在于约15%的多发性骨髓瘤中。这种基因重排导致FGFR3基因和MMSET基因的转录激活和过表达,然而,在大约15%的病例中,由于重排,只有MMSET而不是FGFR3过表达,这导致了MMSET表达的失调是这种多发性骨髓瘤发病机制的核心。MMSET具有SET结构域,先前在组蛋白甲基转移酶和染色质调节因子中发现的其他几个蛋白质结构域中发现。已经证实MMSET蛋白在t(4;14)易位的骨髓瘤细胞中显著过表达。初步数据表明MMSET具有转录辅助因子的特性,包括定位于细胞核,能够结合序列特异性转录因子,包括锌指蛋白ZNF331,转录辅助因子和组蛋白去乙酰化酶。此外,MMSET具有组蛋白甲基转移酶活性,与其他此类蛋白相比,在特异性方面可能存在显着差异。这些数据导致我们的首要假设,即MMSET的异常过表达导致B细胞中基因表达的失调,从而导致骨髓瘤的发病。我们的具体目标是:1)确定MMSET的转录功能,2)利用功能增益和功能丧失策略确定MMSET对骨髓瘤细胞生长的生物活性,3)表征MMSET转录复合物和基因调控的伴侣蛋白,4)鉴定MMSET调控的与多发性骨髓瘤相关的基因。
英文摘要
DESCRIPTION (provided by applicant): Multiple myeloma (MM) represents the malignant transformation of plasma cells, differentiated, post-germinal center B-cells adapted for the production of large quantities of antibody. Multiple myeloma is one of the commonest hematological malignancies and despite the advent of several new therapies such as proteosome inhibitors and thalidomide and the use of stem cell transplant consolidation, the disease is incurable with a median survival of about three years. The pathogenesis of this disease for many years was quite obscure, but over the past decade progress has been made based upon the characterization of consistent chromosomal translocations involving the immunoglobulin heavy chain (IgH). These translocations implicate particular genes in the pathogenesis of myeloma. MMSET (MULTIPLE MYELOMA SET DOMAIN) gene was identified at the breakpoint of the t(4;14) translocation, present in ~15% of multiple myeloma. This gene rearrangement leads to the transcriptional activation and overexpression of the FGFR3 gene and the MMSET gene, however in about 15% of cases only MMSET and not FGFR3 is overexpressed due to the rearrangement leading to the idea that deregulation of MMSET expression is central to the pathogenesis of this form of multiple myeloma. MMSET has a SET domain previously identified in histone methyl transferases and several other protein domains found in chromatin regulators. It has been confirmed that the MMSET protein is significantly overexpressed in myeloma cells harboring the t(4;14) translocation. The preliminary data indicates that MMSET has proprieties of a transcriptional co-factor, including localization to the nucleus, the ability to bind to sequence specific transcription factors including the zinc finger protein ZNF331 and transcriptional co-factors and histone deacetylases. In addition MMSET has histone methyl transferase activity which may be significantly different in terms of specificity when compared to other such proteins. These data lead to our overarching hypothesis that aberrant overexpression of MMSET leads to deregulated gene expression in B cells, contributing to the pathogenesis of myeloma. Our specific aims are: 1) To determine the transcriptional functions of MMSET, 2) To determine the biological activity of MMSET on Myeloma Cell Growth using gain of function and loss of function strategies, 3) To characterize the MMSET transcriptional complex and partner proteins for gene regulation, 4) To identify genes regulated by MMSET relevant to Multiple Myeloma.
期刊论文(8)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1158/2159-8290.cd-12-0076
发表时间: 2012-05
期刊: Cancer discovery
影响因子: 28.2
作者: [Popovic R, Licht JD]
通讯作者: Licht JD
DOI: 10.1016/j.ccr.2013.12.019
发表时间: 2014-01-13
期刊: Cancer cell
影响因子: 50.3
作者: [Licht JD, Shortt J, Johnstone R]
通讯作者: Johnstone R
DOI: 10.1038/onc.2016.116
发表时间: 2016-11-10
期刊: Oncogene
影响因子: 8
作者: [Shah MY, Martinez-Garcia E, Phillip JM, Chambliss AB, Popovic R, Ezponda T, Small EC, Will C, Phillip MP, Neri P, Bahlis NJ, Wirtz D, Licht JD]
通讯作者: Licht JD
DOI: 10.1038/leu.2012.269
发表时间: 2013-03
期刊: Leukemia
影响因子: 11.4
作者: []
通讯作者:
共 6 条
    Exploring microRNA degradation in T-cell acute lymphoblastic leukemia
    • 批准号:
      10717486
    • 项目类别:
    • 资助金额:
      $50.38万
    • 财政年份:
      2023
    • 负责人:
      Jonathan D. Licht
    • 依托单位:
    UF Health Cancer Center Support Grant - Training Navigator Supplement
    • 批准号:
      10892335
    • 项目类别:
    • 资助金额:
      $19.59万
    • 财政年份:
      2023
    • 负责人:
      Jonathan D. Licht
    • 依托单位:
    University of Florida Health Cancer Center Support Grant
    • 批准号:
      10625750
    • 项目类别:
    • 资助金额:
      $213.5万
    • 财政年份:
      2023
    • 负责人:
      Jonathan D. Licht
    • 依托单位:
    Developmental Funds
    • 批准号:
      10625759
    • 项目类别:
    • 资助金额:
      $30.5万
    • 财政年份:
      2023
    • 负责人:
      Jonathan D. Licht
    • 依托单位:
    海外基金